SCHEMBL22019477

SCHEMBL22019477

CCCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1)C(C)C)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ NPY2R P49146 7/20 0.44
▸ NPY4R P50391 7/20 0.44
▸ NPY5R Q15761 7/20 0.44
▸ NPY1R P25929 5/20 0.44
▸ CALCR P30988 8/20 0.43
▸ RAMP3 O60896 7/20 0.43
▸ APLNR P35414 1/20 0.42
▸ TFPI P10646 1/20 0.42
▸ NMUR2 Q9GZQ4 1/20 0.42
▸ NMUR1 Q9HB89 1/20 0.42
▸ NMBR P28336 1/20 0.42
▸ GRPR P30550 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25524938 0.96 APLNR (0.44) NPY2RNPY4RNPY5RNPY1RCALCR
SCHEMBL25524960 0.96 RAMP3 (0.46) NPY2RNPY4RNPY5RNPY1RCALCR
SCHEMBL25524928 0.96 APLNR (0.45) NPY2RNPY4RNPY5RNPY1RCALCR
SCHEMBL25524949 0.95 F2 (0.45) NPY2RNPY4RNPY5RNPY1RCALCR
SCHEMBL22018329 0.95 NPY2R (0.47) NPY2RNPY4RNPY5RNPY1RAPLNR
SCHEMBL25524962 0.94 NMUR2 (0.46) NPY2RNPY4RNPY5RNPY1RCALCR
SCHEMBL29308339 0.94 NPY2R (0.45) NPY2RNPY4RNPY5RNPY1RTFPI
SCHEMBL22018604 0.92 APLNR (0.45) NPY2RNPY4RNPY5RNPY1RCALCR
SCHEMBL22018328 0.92 NPY2R (0.47) NPY2RNPY4RNPY5RNPY1RCALCR
SCHEMBL22019191 0.92 NPY2R (0.46) NPY2RNPY4RNPY5RNPY1RCALCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020099925-A2 PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES YUYU PHARMA, INC. (KR) 2020-05-22 — — WO disclosed
Send feedback